FY2026 Earnings Estimate for Disc Medicine Issued By Wedbush

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Research analysts at Wedbush boosted their FY2026 earnings estimates for Disc Medicine in a research note issued to investors on Tuesday, January 21st. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($3.96) per share for the year, up from their previous forecast of ($4.19). Wedbush currently has a "Outperform" rating and a $90.00 target price on the stock. The consensus estimate for Disc Medicine's current full-year earnings is ($4.07) per share. Wedbush also issued estimates for Disc Medicine's FY2027 earnings at $2.64 EPS.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, beating analysts' consensus estimates of ($1.04) by $0.15.

Several other research analysts have also recently commented on IRON. HC Wainwright restated a "buy" rating and set a $118.00 target price on shares of Disc Medicine in a report on Tuesday. Morgan Stanley upgraded shares of Disc Medicine from an "equal weight" rating to an "overweight" rating and set a $85.00 price objective for the company in a research note on Tuesday, November 5th. Jefferies Financial Group assumed coverage on Disc Medicine in a report on Wednesday, October 23rd. They issued a "buy" rating and a $89.00 price objective for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $85.00 target price on shares of Disc Medicine in a report on Tuesday, October 15th. Finally, Stifel Nicolaus raised their price target on Disc Medicine from $79.00 to $90.00 and gave the company a "buy" rating in a research note on Tuesday, December 10th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Disc Medicine has a consensus rating of "Buy" and an average price target of $88.50.

Disc Medicine Price Performance

NASDAQ:IRON traded down $1.51 during trading hours on Thursday, reaching $56.99. 2,108,707 shares of the stock were exchanged, compared to its average volume of 498,336. The stock has a market cap of $1.70 billion, a PE ratio of -14.32 and a beta of 0.75. Disc Medicine has a twelve month low of $25.60 and a twelve month high of $77.60. The firm has a 50 day moving average of $62.73 and a 200 day moving average of $53.69.

Insider Transactions at Disc Medicine

In other news, Director William Richard White sold 7,136 shares of the firm's stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider William Jacob Savage sold 9,158 shares of the company's stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $59.64, for a total transaction of $546,183.12. Following the completion of the transaction, the insider now owns 40,405 shares in the company, valued at approximately $2,409,754.20. This trade represents a 18.48 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 85,758 shares of company stock worth $5,400,990. 4.24% of the stock is owned by company insiders.

Institutional Trading of Disc Medicine

Several hedge funds have recently added to or reduced their stakes in IRON. Amalgamated Bank boosted its holdings in Disc Medicine by 76.9% in the 2nd quarter. Amalgamated Bank now owns 568 shares of the company's stock valued at $26,000 after purchasing an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Disc Medicine by 45.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company's stock valued at $54,000 after buying an additional 337 shares during the period. Quest Partners LLC acquired a new stake in Disc Medicine during the third quarter worth approximately $131,000. Quantbot Technologies LP bought a new position in Disc Medicine during the 3rd quarter worth $146,000. Finally, Intech Investment Management LLC acquired a new position in Disc Medicine in the 3rd quarter valued at $228,000. 83.70% of the stock is owned by institutional investors and hedge funds.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.